Okazaki Lab | Publications

Jin J, Ogawa T, Hojo N, Kryukov K, Shimizu K, Ikawa T, Imanishi T, Okazaki T, and Shiroguchi K.
Robotic data acquisition with deep learning enables cell image-based prediction of transcriptomic phenotypes.
Proc Natl Acad Sci USA. 120(1):e2210283120, 2023

Maruhashi T, Sugiura D, Okazaki IM, Shimizu K, Maeda TK, Ikubo J, Yoshikawa H, Maenaka K, Ishimaru N, Kosako H, Takemoto T, and Okazaki T.
Binding of LAG-3 to stable peptide-MHCII limits T cell function and suppresses autoimmunity and anti-cancer immunity.
Immunity, 55(5):912-924.e8, 2022

Sugiura D, Okazaki IM, Maeda TK, Maruhashi T, Shimizu K, Arakaki R, Takemoto T, Ishimaru N, and Okazaki T.
PD-1 agonism by anti-CD80 antibody inhibits T cell activation and alleviates autoimmunity.
Nature Immunology, 23(3):399-410, 2022

Sugiura D, Shimimzu K, Maruhashi T, Okazaki IM, and Okazaki T.
T cell-intrinsic and -extrinsic regulation of PD-1 function.
International Immunology, 33(12):693-698, 2021

Kanda Y, Okazaki T, and Katakai T.
Motility dynamics of T cells in tumor-draining lymph nodes: a rational indicator of antitumor response and immune checkpoint blockade.
Cancers, 13(18):4616, 2021

Shimizu K, Sugiura D, Okazaki IM, Maruhashi T, Takemoto T, and Okazaki T.
PD-1 preferentially inhibits the activation of low affinity T cells.
Proc Natl Acad Sci USA. 118(35):e2107141118, 2021

Maruhashi T, Sugiura D, Okazaki IM, and Okazaki T.
LAG-3: from molecular functions to clinical applications.
J Immunother Cancer, 8(2):e001014, 2020.

Shimizu K, Sugiura D, Okazaki IM, Maruhashi T, Takegami Y, Cheng C, Ozaki S, and Okazaki T.
PD-1 imposes qualitative control of cellular transcriptomes in response to T cell activation.
Molecular Cell, 77(5):937-950, 2020

Maeda N, Maruhashi T, Sugiura D, Shimizu K, Okazaki IM, and Okazaki T.
Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells.
Journal of Biological Cheistry, 294(52): 19896-19906, 2019

Okazaki T and Okazaki IM.
Stimulatory and inhibitory co-signals in autoimmunity.
Advances in Experimental Medicine and Biology, 1189: 213-232, 2019

Okamura H, Okazaki IM, Shimizu K, Maruhashi T, Sugiura D, Mizuno R, and Okazaki T.
PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions.
J Autoimmunity, 105: 102296, 2019

Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, and Okazaki T.
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses.
Science, 364(6440): 558-566, 2019

Mizuno R, Sugiura D, Shimizu K, Maruhashi T, Watada M, Okazaki IM, and Okazaki T.
PD-1 primarily targets TCR signal in the inhibition of functional T cell activation.
Frontiers in Immunology, 10: 630, 2019

Maeda TK, Sugiura D, Okazaki IM, Maruhashi T, and Okazaki T.
Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.
Journal of Biological Chemistry, 294(15): 6017-6026, 2019

Mizuno R, Maruhashi T, Sugiura D, Shimizu K, Watada M, Okazaki IM, and Okazaki T.
PD-1 efficiently inhibits T cell activation even in the presence of co-stimulation through CD27 and GITR.
Biochemical and Biophysical Research Communications, 511(3): 491-497, 2019

Maruhashi T, Okazaki IM, Sugiura D, Takahashi S, Maeda TK, Shimizu K, and Okazaki T.
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII.
Nature Immunology, 19(12): 1415-1426, 2018

Nishijima H, Kajimoto T, Matsuoka Y, Mouri Y, Morimoto J, Matsumoto M, Kawano H, Nishioka Y, Uehara H, Izumi K, Tsuneyama K, Okazaki IM, Okazaki T, Hosomichi K, Shiraki A, Shibutani M, Mitsumori K, and Matsumoto M.
Paradoxical development of polymyositis-like autoimmunity through augmented expression of autoimmune regulator (AIRE).
Journal of Autoimmunity, 86: 75-92, 2018

Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, and Irimura T.
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.
Cancer Science, 107(2): 189-202, 2016

Okazaki T, Chikuma S, Iwai Y, Fagarasan S, and Honjo T.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Nature Immunology, 14(12): 1212-1218, 2013

Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, and Watanabe N.
TNF-α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression.
Clinical Immunology, 146(1): 15-25, 2013

Sugino Y, Nishikawa N, Yoshimura K, Kuno S, Hayashi Y, Yoshimura N, Okazaki T, Kanematsu A, and Ogawa O.
BALB/c-Fcgr2bPdcd1 mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis.
Scientific Reports, 2: 317, 2012

Jin HT, Ahmed R, and Okazaki T.
Role of PD-1 in Regulating T-Cell Immunity.
Current Topics in Microbiology and Immunology, 350:17-37, 2011

Iwamoto S, Kido M, Aoki N, Nishiura H, Maruoka R, Ikeda A, Okazaki T, Chiba T, and Watanabe N.
IFN-g is reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach.
Autoimmunity, 45(2): 186-198, 2012

Kayama H, Ueda Y, Sawa Y, Jeon SG, Ma JS, Okumura R, Kubo A, Ishii M, Okazaki T, Murakami M, Yamamoto M, Yagita H, and Takeda K.
Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis.
Proceedings of the National Academy of Sciences of the USA, 109(13): 5010-5015, 2012

Chikuma S, Suita N, Okazaki IM, Shibayama S, and Honjo T.
TRIM28 prevents autoinflammatory T cell development in vivo.
Nature Immunology, 13(6): 596-603, 2012

Okazaki T, Okazaki IM, Wang J, Sugiura D, Nakaki F, Yoshida T, Kato Y, Fagarasan S, Muramatsu M, Eto T, Hioki K, and Honjo T.
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice.
Journal of Experimental Medicine, 208(2): 395-407, 2011

Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R, Tanaka J, Watanabe T, Tanaka Y, Okazaki T, Chiba T, and Watanabe N.
Dysregulated generation of follicular helper T cells in the spleen triggers fatal autoimmune hepatitis in mice.
Gastroenterology, 140(4): 1322-1333, 2011

Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, and Honjo T.
Interferon a directly promotes programmed-cell-death-1 transcription and limits the duration of T cell-mediated immunity.
Journal of Immunology, 186(5): 2772-2779,2011

Okazaki IM, Okawa K, Kobayashi M, Yoshikawa K, Kawamoto S, Nagaoka H, Shinkura R, Kitawaki Y, Taniguchi H, Natsume T, Iemura S, and Honjo T.
Histone chaperone Spt6 is required for class switch recombination but not somatic hypermutation.
Proceedings of the National Academy of Sciences of the USA, 108(19): 7920-7925, 2011

Sakai S, Kawamura I, Okazaki T, Tsuchiya K, Uchiyama R, and Mitsuyama M.
PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guérin.
International Immunology, 22(9): 915-925, 2010

Kasagi S, Kawano S, Okazaki T, Honjo T, Morinobu A, Hatachi S, Shimatani S, Tanaka Y, Minato N, and Kumagai S.
Anti-PD-1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.
Journal of Immunology, 184(5): 2337-2347, 2010

Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, Hiai H, Honjo T, and Okazaki T.
PD-1 deficiency results in the development of fatal myocarditis in MRL mice.
International Immunology, 22(6): 443-452, 2010

Hino S, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, and Tokura Y.
Tumor cell expression of programmed cell death 1 ligand 1 is a prognostic factor for malignant melanoma.
Cancer, 116(7): 1757-1766, 2010

Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida Y, Shibayama S, Okazaki T, and Honjo T.
PD-1-mediated suppression of IL-2 production induces CD8+ T-cell anergy in vivo.
Journal of Immunology, 182(11): 6682-6689, 2009

Jiang F, Yoshida T, Nakaki F, Terawaki S, Chikuma S, Kato Y, Okazaki IM, Honjo T, and Okazaki T.
Identification of QTLs that modify peripheral neuropathy in NOD.H2b–Pdcd1–/– mice.
International Immunology, 21(5): 499-509, 2009

Sugita S, Usui Y, Horie S, Futagami Y, Aburatani H, Okazaki T, Honjo T, Takeuchi M, and Mochizuki M.
T cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
Investigative Ophthalmology & Visual Science, Jun;50(6): 2862-70, 2009

Kobayashi M, Aida M, Nagaoka H, Begum NA, Kitawaki Y, Nakata M, Stanlie A, Doi T, Kato L, Okazaki IM, Shinkura R, Muramatsu M, Kinoshita K, and Honjo T.
AID-induced decrease in topoisomerase 1 induces DNA structural alteration and DNA cleavage for class switch recombination.
Proceedings of the National Academy of Sciences of the USA, 106(52): 22375-22380, 2009

Sabouri Z, Okazaki IM, Shinkura R, Begum N, Nagaoka H, Tsuchimoto D, Nakabeppu Y, and Honjo T.
Apex2 is required for efficient somatic hypermutation but not for class switch recombination of immunoglobulin genes.
International Immunology, 21(8): 947-955, 2009

Shivarov V, Shinkura R, Doi T, Begum NA, Nagaoka H, Okazaki IM, Ito S, Nonaka T, Kinoshita K, and Honjo T.
Molecular mechanism for generation of antibody memory.
Philosophical Transactions of the Royal Society B: Biological Sciences, 364(1517): 569-575, 2009

Takai A, Toyoshima T, Uemura M, Kitawaki Y, Marusawa H, Hiai H, Yamada S, Okazaki IM, Honjo T, Chiba T, and Kinoshita K.
A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations.
Oncogene, 28(4): 469-478, 2009

Kido M, Watanabe N, Okazaki T, Akamatsu T, Tanaka J, Saga K, Nishio A, Honjo T, and Chiba T.
Fatal autoimmune hepatitis induced by concurrent loss of naturally arising regulatory T cells and PD-1-mediated signaling.
Gastroenterology, 135(4): 1333-43, 2008

Yoshida T, Jiang F, Honjo T, and Okazaki T.
PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes on NOD background.
Proceedings of the National Academy of Sciences of the USA, 105(9): 3533-3538, 2008

Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, and Garboczi DN.
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.
Proceedings of the National Academy of Sciences of the USA, 105(8): 3011-3016, 2008

Green KA, Okazaki T, Honjo T, Cook WJ, and Green WR.
The programmed death-1 and interleukin-ao pathway play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome.
Journal of Virology, 82(5): 2456-2469, 2008

Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, and Chiba T.
Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression.
International Journal of Cancer, 123(12): 2735-2740, 2008

Okazaki T and Honjo T.
PD-1 and PD-1 ligands: from discovery to clinical application.
International Immunology, 19(7): 813-824, 2007

Terawaki S, Tanaka Y, Nagakura T, Hayashi T, Shibayama S, Muroi K, Okazaki T, Mikami B, Garboczi DN, Honjo T, and Minato N.
Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
International Immunology, 19(7): 881-890, 2007

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, and Fujii S.
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Proceedings of the National Academy of Sciences of the USA, 104(9): 3360-3365, 2007

Okazaki IM, Kotani A, and Honjo T.
Role of AID in tumorigenesis.
Advances in Immunology, 94: 245-273, 2007

Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watashi K, Shimotohno K, Honjo T, and Chiba T.
Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling.
Oncogene, 26(38): 5587-5595, 2007

Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, and Chiba T.
Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium.
Nature Medicine, 13(4): 470-476, 2007

Shinkura R, Okazaki IM, Muto T, Begum NA, and Honjo T.
Regulation of AID function in vivo.
Advances in Experimental Medicine and Biology, 596: 71-81, 2007

Kotani A, Kakazu N, Tsuruyama T, Okazaki IM, Muramatsu M, Kinoshita K, Nagaoka H, Yabe D, and Honjo T.
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice.
Proceedings of the National Academy of Sciences of the USA, 104(5): 1616-1620, 2007

Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, and Chiba T.
Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis.
International Journal of Cancer, 120(3): 469-476, 2007

Okazaki T and Honjo T.
The PD-1-PD-L pathway and immunological tolerance.
Trends in Immunology, 27(4): 195-201, 2006

Okazaki T and Honjo T.
Rejuvenating exhausted T cells during chronic viral infection.
Cell, 124(3): 459-461, 2006

Muto T, Okazaki IM, Yamada S, Tanaka Y, Kinoshita K, Muramatsu M, Nagaoka H, and Honjo T.
Negative regulation of activation-induced cytidine deaminase in B cells.
Proceedings of the National Academy of Sciences of the USA, 103(8): 2752-2757, 2006

Okazaki T, Otaka Y, Wang J, Hiai H, Takai T, Ravetch JV and Honjo T.
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice.
Journal of Experimental Medicine, 202(12): 1643-1648, 2005

Kobayashi M, Kawano S, Hatachi S, Kurimoto C, Okazaki T, Iwai Y, Honjo T, Tanaka Y, Minato N, Komori T, Maeda S, and Kumagai S.
Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome.
Journal of Rheumatology, 32(11): 2156-2163, 2005

Okazaki T and Honjo T.
Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy.
Trends in Molecular Medicine, 11(5): 322-326, 2005

Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, and Honjo T.
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.
Proceedings of the National Academy of Sciences of the USA, 102(33): 11823-11828, 2005

Okazaki T and Wang J.
PD-1/PD-L pathway and autoimmunity.
Autoimmunity, 38(7): 353-357, 2005

Probst HC, McCoy K, Okazaki T, Honjo T, and van den Broek M.
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.
Nature Immunology, 6(3): 280-286, 2005

Kotani A, Okazaki IM, Muramatsu M, Kinoshita K, Begum NA, Nakajima T, Saito H, and Honjo T.
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression.
Proceedings of the National Academy of Sciences of the USA, 102(12): 4506-11, 2005

Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, and Honjo T.
Autoantibodies against cardiac troponin I are responsible for the dilated cardiomyopathy in PD-1 deficient mice.
Nature Medicine, 9(12): 1477-1483, 2003

Iwai Y, Terawaki S, Ikegawa M, Okazaki T, and Honjo T.
PD-1 inhibits antiviral immunity at the effector phase in the liver.
Journal of Experimental Medicine, 198(1): 39-50, 2003

Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, and Honjo T.
Constitutive expression of AID leads to tumorigenesis.
Journal of Experimental Medicine, 197(9): 1173-1181, 2003

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, and Minato N.
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Proceedings of the National Academy of Sciences of the USA, 99(19): 12293-12297, 2002

Kanazawa N, Okazaki T, Nishimura H, Tashiro K, Inaba K, and Miyachi Y.
DCIR acts as an inhibitory receptor depending on its immunoreceptor tyrosine-based inhibitory motif.
Journal of Investigative Dermatology, 118(2): 261-266, 2002

Okazaki T, Iwai Y, and Honjo T.
New regulatory co-receptors: inducible co-stimulator and PD-1.
Current Opinion in Immunology, 14(6): 779-782, 2002

Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, Minato N, and Honjo T.
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
Immunology Letters, 84(1): 57-62, 2002

Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, and Honjo T.
Microanatomical localization of PD-1 in human tonsils.
Immunology Letters, 83(3): 215-220, 2002

Yoshikawa K, Okazaki IM, Eto T, Kinoshita K, Muramatsu M, Nagaoka H, and Honjo T.
AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts.
Science. 296(5575): 2033-2036, 2002

Okazaki IM, Kinoshita K, Muramatsu M, Yoshikawa K, and Honjo T.
The AID enzyme induces class switch recombination in fibroblasts.
Nature. 416(6878): 340-345, 2002

Okazaki T, Maeda A, Nishimura H, Kurosaki T, and Honjo T.
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.
Proceedings of the National Academy of Sciences of the USA, 98(24): 13866-133871, 2001

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, and Freeman GJ.
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nature Immunology, 2(3): 261-268, 2001

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, and Honjo T.
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
Science, 291(5502): 319-322, 2001

Okazaki T, Iwai Y, Nishimura H, and Honjo T.
The regulation of PD-1/PD-L1 pathway and autoimmune diseases.
In: Activating and inhibitory immunoglobulin-like receptors, Eds. Cooper, M.D., Takai, T. and Ravetch, J.V. (Springer-Verlag, Tokyo), 211-214, 2001

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, and Honjo T.
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Journal of Experimental Medicine, 192(7): 1027-1034, 2000

Mandelboim O, Kent S, Davis DM, Wilson SB, Okazaki T, Jackson R, Hafler D, and Strominger JL.
Natural killer activating receptors trigger interferon gamma secretion from T cells and natural killer cells.
Proceedings of the National Academy of Sciences of the USA, 95(7): 3798-3803, 1998

Minoguchi S, Taniguchi Y, Kato H, Okazaki T, Strobl LJ, Zimber-Strobl U, Bornkamm GW, and Honjo T.
RBP-L, a transcription factor related to RBP-Jkappa.
Molecular and Cellular Biology, 17(5): 2679-2687, 1997

Satoh N, Ogawa Y, Katsuura G, Tsuji T, Masuzaki H, Hiraoka J, Okazaki T, Tamaki M, Hayase M, Yoshimasa Y, Nishi S, Hosoda K, and Nakao K.
Pathophysiological significance of the obese gene product, leptin, in ventromedial hypothalamus (VMH)-lesioned rats: evidence for loss of its satiety effect in VMH-lesioned rats.
Endocrinology, 138(3): 947-954, 1997

Okazaki T, Ogawa Y, Tamura N, Mori K, Isse N, Aoki T, Rochelle JM, Taketo MM, Seldin MF, and Nakao K.
Genomic organization, expression, and chromosomal mapping of the mouse adrenomedullin gene.
Genomics, 37(3): 395-399, 1996

Takaya K, Ogawa Y, Isse N, Okazaki T, Satoh N, Masuzaki H, Mori K, Tamura N, Hosoda K, and Nakao K.
Molecular cloning of rat leptin receptor isoform complementary DNAs--identification of a missense mutation in Zucker fatty (fa/fa) rats.
Biochemical and Biophysical Research Communications, 225(1): 75-83, 1996

Isse N, Ogawa Y, Tamura N, Masuzaki H, Mori K, Okazaki T, Satoh N, Shigemoto M, Yoshimasa Y, Nishi S, Hosoda K, Inazawa J, and Nakao, K.
Structural organization and chromosomal assignment of the human obese gene.
Journal of Biological Chemistry, 270(46): 27728-27733, 1995

Ogawa Y, Masuzaki H, Isse N, Okazaki T, Mori K, Shigemoto M, Satoh N, Tamura N, Hosoda K, Yoshimasa Y, Jingami H, Kawada T, and Nakao K.
Molecular cloning of rat obese cDNA and augmented gene expression in genetically obese Zucker fatty (fa/fa) rats.
Journal of Clinical Investigation, 96(3): 1647-1652, 1995

Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, Mori K, Tamura N, Hosoda K, Yoshimasa Y, Jingami H, Kawada T, and Nakao K.
Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue.
Diabetes, 44(7): 855-858, 1995